MediWound Ltd. will host a virtual KOL event on Jan 8, 2025, discussing EscharEx®, a biologic drug in late-stage development for chronic wound debridement, including the Phase III VALUE study in venous leg ulcers and its commercial potential. The event features clinical experts John C. Lantis II, Vickie R. Driver, and Robert J. Snyder, discussing EscharEx's Phase II results, upcoming Phase III study, unmet needs in wound care, and competitive advantages.